IDXX · Nasdaq · CIK 0000874716
IDEXX LABORATORIES INC /DE
IDEXX LABORATORIES INC /DE’s most recent SEC filing in our snapshot is a Form 4 filed on Sep 9, 2026. In fiscal 2025 (year ended Dec 31, 2025) it reported revenue of $4.3B and net income of $1.1B, according to its XBRL data on EDGAR. Its EDGAR record lists 41 Form 4 insider filings from the 12 months before our last refresh.
SEC EDGAR snapshot updated Oct 27, 2026, 11:27 PM EDT. See all filings on sec.gov.
Company overview
- Legal name (as filed)
- IDEXX LABORATORIES INC /DE
- Ticker
- IDXX
- SEC Central Index Key (CIK)
- 0000874716
- Industry (SIC)
- In Vitro & In Vivo Diagnostic Substances (code 2835)
- Business address
- WESTBROOK, ME
- State or country of incorporation
- DE
- Fiscal year ends
- December 31
- SEC filer category
- Large accelerated filer
- Position in SEC ticker list
- #355 of the 3,000 companies we track
Five-year financial highlights
Full-year figures from IDEXX LABORATORIES INC /DE’s annual reports, as tagged in XBRL and published by the SEC. Amounts are in U.S. dollars; the fiscal year is named for the calendar year in which it ends.
| Item | FY2021 ended Dec 31, 2021 | FY2022 ended Dec 31, 2022 | FY2023 ended Dec 31, 2023 | FY2024 ended Dec 31, 2024 | FY2025 ended Dec 31, 2025 |
|---|---|---|---|---|---|
| Revenue | $3.2B | $3.4B | $3.7B | $3.9B | $4.3B |
| Net income | $744.8M | $679.1M | $845.0M | $887.9M | $1.1B |
| Diluted EPS | $8.60 | $8.03 | $10.06 | $10.67 | $13.08 |
| Total assets | $2.4B | $2.7B | $3.3B | $3.3B | $3.4B |
| Cash and equivalents | $144.5M | $112.5M | $453.9M | $288.3M | $180.1M |
XBRL tags used: revenue = RevenueFromContractWithCustomerExcludingAssessedTax; netIncome = NetIncomeLoss; assets = Assets; eps = EarningsPerShareDiluted; cash = CashAndCashEquivalentsAtCarryingValue. EPS is shown as originally reported for each year and may not be adjusted for later stock splits. A dash means the company did not report that item in a form we could match.
How to read these numbers
Revenue is the money a company brings in from selling its products and services; net income is what is left after all expenses, interest and taxes. Diluted EPS spreads net income across every share that could exist if options and convertible securities were exercised. Total assets and cash are balance-sheet figures measured on the last day of the fiscal year. For the full story — segment results, one-time charges, guidance — read Management’s Discussion and Analysis in the Form 10-K.
Advertisement
Latest key reports
The most recent filing of each major report type, even if it falls outside the 40 newest filings below.
| Filed | Form | What it is | Original |
|---|---|---|---|
| Feb 20, 2026 | 10-K | Annual report· period Dec 31, 2025 | Document · Index |
| Aug 4, 2026 | 10-Q | Quarterly report· period Jun 30, 2026 | Document · Index |
| Aug 4, 2026 | 8-K | Results of operations· period Aug 4, 2026 | Document · Index |
| Mar 27, 2026 | DEF 14A | Definitive proxy statement· period Dec 31, 2025 | Document · Index |
Recent SEC filings
The 40 newest documents filed by or about IDEXX LABORATORIES INC /DE, by form type:
| Filed | Form | What it is | Original |
|---|---|---|---|
| Sep 9, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Sep 4, 2026 | Document · Index |
| Sep 4, 2026 | 144 | Notice of proposed sale of securities | Document · Index |
| Aug 24, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Aug 20, 2026 | Document · Index |
| Aug 4, 2026 | 8-K | Results of operations· period Aug 4, 2026 | Document · Index |
| Aug 4, 2026 | 10-Q | Quarterly report· period Jun 30, 2026 | Document · Index |
| Aug 3, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Jul 30, 2026 | Document · Index |
| Jun 2, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Jun 1, 2026 | Document · Index |
| Jun 1, 2026 | SD | Specialized disclosure report (conflict minerals) | Document · Index |
| May 20, 2026 | 144 | Notice of proposed sale of securities | Document · Index |
| May 15, 2026 | 8-K | Charter, bylaws or fiscal year change; Shareholder vote results· period May 12, 2026 | Document · Index |
| May 14, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period May 12, 2026 | Document · Index |
| May 14, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period May 12, 2026 | Document · Index |
| May 14, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period May 12, 2026 | Document · Index |
| May 14, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period May 12, 2026 | Document · Index |
| May 14, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period May 12, 2026 | Document · Index |
| May 14, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period May 12, 2026 | Document · Index |
| May 14, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period May 12, 2026 | Document · Index |
| May 14, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period May 12, 2026 | Document · Index |
| May 14, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period May 12, 2026 | Document · Index |
| May 11, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period May 7, 2026 | Document · Index |
| May 11, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period May 7, 2026 | Document · Index |
| May 11, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period May 7, 2026 | Document · Index |
| May 11, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period May 7, 2026 | Document · Index |
| May 11, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period May 7, 2026 | Document · Index |
| May 11, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period May 7, 2026 | Document · Index |
| May 5, 2026 | 8-K | Results of operations· period May 5, 2026 | Document · Index |
| May 5, 2026 | 10-Q | Quarterly report· period Mar 31, 2026 | Document · Index |
| May 4, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Apr 30, 2026 | Document · Index |
| Apr 30, 2026 | SCHEDULE 13G | Passive beneficial ownership report (over 5%) | Document · Index |
| Mar 27, 2026 | ARS | ARS· period Dec 31, 2025 | Document · Index |
| Mar 27, 2026 | DEFA14A | Additional proxy soliciting materials | Document · Index |
| Mar 27, 2026 | DEF 14A | Definitive proxy statement· period Dec 31, 2025 | Document · Index |
| Mar 27, 2026 | SCHEDULE 13G/A | Passive beneficial ownership report (over 5%) | Document · Index |
| Mar 26, 2026 | 8-K | Director or officer change· period Mar 24, 2026 | Document · Index |
| Mar 13, 2026 | PRE 14A | PRE 14A· period Dec 31, 2025 | Document · Index |
| Mar 5, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Mar 3, 2026 | Document · Index |
| Mar 5, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Mar 3, 2026 | Document · Index |
| Mar 3, 2026 | 144 | Notice of proposed sale of securities | Document · Index |
| Mar 3, 2026 | 4/A | Statement of changes in beneficial ownership (insider trade)· period Feb 12, 2026 | Document · Index |
| Mar 2, 2026 | 4 | Statement of changes in beneficial ownership (insider trade)· period Feb 26, 2026 | Document · Index |
Insider filing activity
41 Form 4 filings appear in IDEXX LABORATORIES INC /DE’s EDGAR record between Oct 28, 2025 and our last refresh. Most are reports by the company’s own directors, officers and 10% owners, but EDGAR also lists a Form 4 under a company when the company itself is the insider — for example, when it owns more than 10% of another public company. Foreign private issuers’ own insiders generally do not file Form 4. A high count is not by itself a signal: many Form 4s report routine stock awards, tax withholding or sales under pre-arranged Rule 10b5-1 plans. Open each filing to see the transaction code, share count and price. What a Form 4 shows.
Advertisement
Other companies in In Vitro & In Vivo Diagnostic Substances
- LNTH Lantheus Holdings, Inc.
- NEOG NEOGEN CORP
- CLDX Celldex Therapeutics, Inc.
- NTLA Intellia Therapeutics, Inc.
- QDEL QuidelOrtho Corp
- ACHV ACHIEVE LIFE SCIENCES, INC.
- MYGN MYRIAD GENETICS INC
All 8 companies in In Vitro & In Vivo Diagnostic Substances· Companies headquartered in Maine
On Amazon
Popular tools for investors
As an Amazon Associate I earn from qualifying purchases.
Source
- U.S. Securities and Exchange Commission, EDGAR submissions for CIK 0000874716 and XBRL company facts. IDEXX LABORATORIES INC /DE on EDGAR.
- Snapshot updated Oct 27, 2026, 11:27 PM EDT. The SEC does not endorse OpenFilings. Company names and tickers are used only to identify the filer; no logos are shown.
Not investment advice. This page summarizes public SEC filings for information only. Figures may contain errors or omissions; confirm everything in the original filing before relying on it.
Advertisement